Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report
Connect-ROD – development and qualitative evaluation of a community-based group intervention to support well-being in patients with a rare or orphan disease
5 July 2024
Connect-ROD – development and qualitative evaluation of a community-based group intervention to support well-being in patients with a rare or orphan disease
5 July 2024

Medicine 103(27):p e38854, July 05, 2024. | DOI: 10.1097/MD.0000000000038854

Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report

Authors: He, Zhe MM1; Dong, Qian MM1; Xi, Yue MM1; Zheng, Rui MD2,*

Affiliation:

  1. Shanxi Medical University, Taiyuan, Shanxi, China
  2. Department of Dermatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Abstract:

Introduction: 

Epidermolysis Bullosa Pruriginosa (EBP) is a persistent, recurring disease that seriously affects quality of life. Fewer than 100 cases of EBP have been reported to date. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, and inhibition of this pathway using Janus kinase (JAK) inhibitors might be a useful therapeutic strategy for these diseases.

Patient concerns: 

A male patient, 28 years of age, was admitted to our hospital because of recurrent papules, nodules, and intense itching on the trunk and extremities for 12 years. Repeated large and intense itching has seriously affected the patient normal life.

Diagnosis: 

The patient was diagnosed with EBP based on examination results.

interventions: 

Oral baricitinib tablets (2 mg, once a day) + Oral desloratadine citrate disodium tablets (8.8 mg, once a day) combined with topical compound flumethasone ointment and Fucidin cream.

outcomes: 

The patient skin rashes had subsided and flattened remarkable, and his itching was markedly relieved. The visual analogue scale (VAS) itching score of the patient gradually declined from 8 to 9 points to 2 to 3 points.

Conclusion: 

This study confirms that baricitinib is effective and feasible in treating EBP, especially in remarkable relieving itching, which rendered new ideas for therapeutic approaches for EBP in the future.

Download: https://journals.lww.com/md-journal/fulltext/2024/07050/epidermolysis_bullosa_pruriginosa_treated_with.8.aspx?context=latestarticles